Solid Biosciences reports adverse effects of Duchenne gene therapy: 4 things to know

Solid Biosciences released its first quarter earnings on May 13, as well as an update on its efforts to develop a gene therapy treatment for Duchenne muscular dystrophy.

Here are four things to know about the Cambridge, Mass.-based life sciences company's progress.

1. Solid reported a net loss of $29.6 million in the first quarter of 2019, nearly double the $15.9 million net loss reported in the first quarter of 2018.

2. The company spent $23.3 million on research and development, and $7 million in general and administrative expenses in the first quarter.

3. After Solid administered its SGT-001 gene therapy to a Duchenne patient in an ongoing study, the patient experienced an elevation of transaminases and an increase in bilirubin, both of which were reported to the FDA as serious adverse events related to the treatment.

4. Despite these adverse reactions, Solid is expanding its SGT-001 clinical trials to several new sites, which will join the University of Florida, the study's first clinical site.

More articles about health IT:
Mohawk Valley Health System to go live on Epic
U of Arizona to develop EHR alerts for patients at risk of drug-induced sudden cardiac death
Livongo adds Boston Children's Hospital CEO to board of directors

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months